heidi merethe hoff naken sorted by

relevance

To identify factors predictive for successful discontinuation of anti-TNF• During this 6 year period she will coordinate both the randomized part and the follow up part of the project.

About the project In the BIOSTOP Study ulcerative colitis patients in remission after at least one year anti-TNF maintenance therapy will be included.

During the randomization period, patients will be monitored by repeated symptom scoring and faecal calprotectin.

To assess the efficacy and safety of restarting anti-TNF treatment after a relapse.

Among the 28 participating centres are all the Norwegian University Hospitals and all medium and larger sized gastroenterology centers in Norway, as well as most of the smaller centers.

National cooperating centers and other cooperating partners Hospitals and centers from all parts of Norway and all four health regions will participate in the BIOSTOP Study.

To identify factors predictive for successful restart of anti-TNF in patients experiencing a relapse Resource utilization, cost-effectiveness and patients reported outcome objectives•.

continuing anti-TNF in UC patients in remiss.

To assess UC-related events hospitalizations, procedures ,cost-effectiveness and effect on health-related quality of life QoL after two years of randomized treatmen Collaboration National coordinating center Ingrid Prytz Berset is the national coordinating investigator of the BIOSTOP study.